Please assess the completion status of the following clinical trial:

Trial Title: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males or females (≥ 18 years, to 75 years)~2. DSM IV TR diagnosis of schizophrenia or schizoaffective disorder (If officially instituted by study initiation: DSM V diagnoses will be used).~3. Ability to provide informed written consent~4. PANSS total score ≥ 60, positive symptom cluster, (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility and unusual thought content with at least 2 items scoring ≥ 4, or one of these items scoring ≥ 5, on a scale ranging from 1 = absent to 7 = extreme~5. Current symptom exacerbation ≥ 2 weeks, but ≤ 1 year~6. Receiving anti-psychotic medications for ≥ 4 weeks~7. For women of child bearing age, a negative pregnancy test at screening.~Exclusion Criteria:~1. Testing positive for illicit substances (marijuana or alcohol use will be assessed on a case by case basis, caffeine and nicotine are excepted)~2. Receiving pharmacological treatment for addictions (naltrexone, suboxone, acamprosate, others) will be reviewed on a case by case basis~3. Seriously unstable medical illnesses~4. Pregnant or breast feeding women~5. Known allergy or history of serious adverse event with WSE~6. Subjects who may require imminent hospitalization (examples: suicidal or aggressive behavior)~7. Currently receiving antibiotics, anti-viral, or anti-parasitic medications~8. Currently receiving immunosuppressive medications (e.g. corticosteroids, chemotherapy or transplantation or HIV/AIDs associated drugs).~9. Currently receiving NSAIDs or Aspirin (\>81 mg/day) on a daily basis or PRN use \> 2x/week (in the last 4 weeks).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sensoril® (Type: EXPERIMENTAL): Sensoril® is a proprietary extract of Withania Somnifera
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).